Get the Stockscreener App
34.84
0.37%
0.13
After Hours:
34.84
Harmony Biosciences Holdings Inc stock is traded at $34.84, with a volume of 514.46K.
It is up +0.37% in the last 24 hours and up +5.67% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$34.71
Open:
$34.92
24h Volume:
514.46K
Relative Volume:
0.77
Market Cap:
$2.00B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
16.51
EPS:
2.11
Net Cash Flow:
$220.18M
1W Performance:
+6.38%
1M Performance:
+5.67%
6M Performance:
-5.66%
1Y Performance:
+2.44%
1-Day Range:
$34.13
$34.96
1-Week Range:
$33.07
$35.08
52-Week Range:
$26.47
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
34.84 | 1.88B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Mizuho Reaffirms “Outperform” on Harmony Biosciences (HRMY) for BP1.15205 Data - MSN
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY) - Yahoo Finance
Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? - Zacks Investment Research
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series | HRMY Stock News - GuruFocus
Harmony Biosciences CEO to Share Latest Company Updates at Exclusive H.C. Wainwright Virtual Conference - Stock Titan
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series - Business Wire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY) - ACCESS Newswire
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise - MSN
Goldman Sachs Resumes Harmony Biosciences Holdings Inc. (HRMY) at Neutral - StreetInsider
Harmony Biosciences stock resumes coverage at Goldman Sachs with Neutral rating - Investing.com Nigeria
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know - Nasdaq
Harmony Biosciences (HRMY) Maintains Buy Rating with Price Target Increase | HRMY Stock News - GuruFocus
Harmony Biosciences stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com South Africa
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY) - Insider Monkey
Harmony Biosciences (HRMY) Price Target Raised by Deutsche Bank Amid Key Trial | HRMY Stock News - GuruFocus
Harmony Biosciences (HRMY) Receives Neutral Rating and Price Tar - GuruFocus
Mizuho reiterates Outperform rating on Harmony Biosciences stock By Investing.com - Investing.com Australia
SEI Select Small Cap ETF Implied Analyst Target Price: $30, Upside Potential for Underlying Holdings - AInvest
Mizuho reiterates Outperform rating on Harmony Biosciences stock - Investing.com
(HRMY) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment - Zacks Investment Research
Top 5 US Stocks To Buy In July 2025 - Investing.com
First Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq
Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data By Investing.com - Investing.com UK
Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement - insights.citeline.com
Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment - MyChesCo
Rhumbline Advisers Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
(HRMY) Investment Analysis - news.stocktradersdaily.com
Equities Analysts Set Expectations for HRMY FY2026 Earnings - Defense World
Harmony Biosciences Presents Preclinical Data Demonstrating Sign - GuruFocus
Harmony Biosciences to begin human trials of narcolepsy drug in 2025 By Investing.com - Investing.com South Africa
Harmony Biosciences to begin human trials of narcolepsy drug in 2025 - Investing.com Canada
HRMY: Harmony Biosciences Shows Promising Preclinical Data for BP1.15205 | HRMY Stock News - GuruFocus
Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 - StreetInsider
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory - MSN
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement System - Defense World
Transcript : Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener
Harmony Biosciences settles patent litigation with Lupin By Investing.com - Investing.com South Africa
Harmony Biosciences, Lupin reach agreement on Wakix generic launch - MSN
Harmony Biosciences: If It Ain't Broke (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation - BioSpace
Harmony Biosciences (HRMY) Settles Patent Dispute with Lupin | HRMY Stock News - GuruFocus
Harmony Biosciences settles patent litigation with Lupin - Investing.com Australia
Harmony Biosciences Strengthens Patent Position With Favorable Settlement In ANDA Litigation - MarketScreener
Harmony Biosciences Strengthens Patent Position With Favorable S - GuruFocus
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):